Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. This year’s metric has recorded a Price decrease of -91.06%. However, over the past six months, we’ve seen a stronger performance of -7.92%. The price of RNAZ fallen by 114.29% over the last 30 days. And in the last five days, it has fallen by -8.52%.
TransCode Therapeutics Inc’s stock has had a tumultuous market performance. The 1-year high for the company’s stock was $21.20 on 10/16/23, and the lowest price during the same period was recorded at $0.22 on 08/14/24.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
52-week price history of RNAZ Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. TransCode Therapeutics Inc’s current trading price is -97.22% away from its 52-week high, while its distance from the 52-week low is 172.82%. The stock’s price range for this period has been between $0.22 and $21.20. The Healthcare sector company’s shares saw a trading volume of about 0.83 million for the day, which was lower than the average daily volume of 1.93 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
TransCode Therapeutics Inc (RNAZ) has experienced a quarterly decline of -14.62% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 10.18M and boasts a workforce of 10 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.6965, with a change in price of -0.0269. Similarly, TransCode Therapeutics Inc recorded 1,559,742 in trading volume during the last 100 days, posting a change of -4.37%.
RNAZ’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for RNAZ stands at 0.17. Similarly, the long-term debt-to-equity ratio is also 0.00.
RNAZ Stock Stochastic Average
As of today, the raw stochastic average of TransCode Therapeutics Inc over the past 50 days is 72.63%. This is a increase compared to the raw stochastic average of the last 20 days, which was recorded at 71.56%. Additionally, the Stochastic %K and %D values for the company were 67.30% and 62.04%, respectively, over the past 20 days.
